MARKET

KTTA

KTTA

Pasithea Therapeutics Corp
NASDAQ
0.5220
+0.0021
+0.40%
After Hours: 0.4896 -0.0324 -6.21% 19:50 11/13 EST
OPEN
0.5650
PREV CLOSE
0.5199
HIGH
0.5800
LOW
0.4641
VOLUME
2.37M
TURNOVER
--
52 WEEK HIGH
2.060
52 WEEK LOW
0.2810
MARKET CAP
17.44M
P/E (TTM)
-0.3522
1D
5D
1M
3M
1Y
5Y
1D
Pasithea Therapeutics Price Target Raised to $4.00/Share From $3.00 by HC Wainwright & Co.
Dow Jones · 2d ago
Pasithea Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 2d ago
HC Wainwright & Co. Maintains Buy on Pasithea Therapeutics, Raises Price Target to $4
Benzinga · 2d ago
Pasithea's PAS-004 Shrinks Skin Tumors in All 15 Evaluable Patients
Benzinga · 2d ago
Pasithea Therapeutics price target raised to $4 from $3 at H.C. Wainwright
TipRanks · 2d ago
Pasithea Reports Tumor Shrinkage With PAS-004 In Neurofibromatosis Trial; Stock Up
NASDAQ · 2d ago
Pasithea Therapeutics presents clinical data from PAS-004-103 study
TipRanks · 2d ago
Pasithea’s PAS-004 Reduces Cutaneous Neurofibromas In All 15 Evaluable Participants, 41% Median Best Reduction, 46% At Planned Phase 2 Doses, With No Treatment-Related Serious Adverse Events
Benzinga · 3d ago
More
About KTTA
Pasithea Therapeutics Corp. is a biotechnology company focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases. The Company is advancing a pipeline of three therapeutic product candidates, with a focus on its lead product candidate, PAS-004, a macrocyclic mitogen-activated protein kinase, or MEK inhibitor. PAS-004 is a small molecule allosteric inhibitor of MEK 1 and 2 (MEK 1/2) for potential use in the treatment of a range of RASopathies, including neurofibromatosis type 1 (NF1) and a number of oncology indications, among others. Its remaining two programs, PAS-001 and PAS-003, are in the earlier stages of development and are based on novel targets for the treatment of CNS disorders that it believes address limitations in the treatment paradigm of the indications it plans to address, which are amyotrophic lateral sclerosis (ALS) for its PAS-003 program, and schizophrenia for its PAS-001 program.

Webull offers Pasithea Therapeutics Corp stock information, including NASDAQ: KTTA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KTTA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KTTA stock methods without spending real money on the virtual paper trading platform.